Related resources
Full-text held externally
- DOI: 10.1093/rheumatology/keu358
- PMID: 25213131
- UKPMCID: 25213131
Search for item elsewhere
University researcher(s)
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Bluett, James; Morgan, Catharine; Cordingley, Lis; Barton, Anne; BRAGGSS; Thurston, Layla; Plant, Darren; Hyrich, Kimme L; Morgan, Ann W; Wilson, Anthony G; Isaacs, John D
Rheumatology (Oxford, England). 2015;54(3):494-499.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- DOI: 10.1093/rheumatology/keu358
- PMID: 25213131
- UKPMCID: 25213131
Abstract
OBJECTIVE: Non-adherence to DMARDs is common, but little is known about adherence to biologic therapies and its relationship to treatment response. The purpose of this study was to investigate the association between self-reported non-adherence to s.c. anti-TNF therapy and response in individuals with RA. METHODS: Participants about to start s.c. anti-TNF therapy were recruited to a large UK multicentre prospective observational cohort study. Demographic information and disease characteristics were assessed at baseline. Self-reported non-adherence, defined as whether the previous due dose of biologic therapy was reported as not taken on the day agreed with the health care professional, was recorded at 3 and 6 months following the start of therapy. The 28-joint DAS (DAS28) was recorded at baseline and following 3 and 6 months of therapy. Multivariate linear regression was used to examine these relationships. RESULTS: Three hundred and ninety-two patients with a median disease duration of 7 years [interquartile range (IQR) 3-15] were recruited. Adherence data were available in 286 patients. Of these, 27% reported non-adherence to biologic therapy according to the defined criteria at least once within the first 6-month period. In multivariate linear regression analysis, older age, lower baseline DAS28 and ever non-adherence at either 3 or 6 months from baseline were significantly associated with a poorer DAS28 response at 6 months to anti-TNF therapy. CONCLUSION: Patients with RA who reported not taking their biologic on the day agreed with their health care professional showed poorer clinical outcomes than their counterparts, emphasizing the need to investigate causes of non-adherence to biologics.
Keyword(s)
adherence; behaviour; biologic therapies; outcome measures; rheumatoid arthritis